A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

PHASE2CompletedINTERVENTIONAL

Enrollment

222

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2015

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

adalimumab

adalimumab administered as subcutaneous injection every other week (EOW)

BIOLOGICAL

ABT-122

ABT-122 administered as subcutaneous injection every other week (EOW)